Radiation Oncology/Hodgkin/Lymphocyte predominant
Jump to navigation Jump to search
Hodgkin's Lymphoma: Lymphocyte Predominant
- Lymphocyte-predominant has a different natural history (especially stages I-II) and response to therapy than classical HL.
- Chemo is not indicated in most early stage cases, and standard is IFRT.
- LP has best prognosis of HL subtypes, but late recurrences common and long-term followup necessary.
NCCN Guidelines[edit | edit source]
- Stage I-IIA: IFRT or regional RT
- Stage I-IIB w/ B sx's: chemotherapy followed by IFRT
- Stage III-IVA: chemotherapy +/- RT –OR— observation (cat 2B) –OR— local RT (palliation only) or rituximab
- Stage III-IVB: chemotherapy +/- RT or rituximab +/- chemo +/- RT
Studies[edit | edit source]
- Germany, 1999 PMID 10071266 — "Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease." Diehl V; J Clin Oncol. 1999 Mar;17(3):776-83.
- GHSG, 2005 PMID 16093276 — "Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)." Nogova L; Ann Oncol. 2005 Oct;16(10):1683-7.
- GHSG, 2008 PMID 18086799 — "Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group." Nogova L; J Clin Oncol